Recruiting
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
- Sponsor
- Noom Inc. (Industry)
- Enrollment
- 2,541 planned
- Conditions
- Obesity & Overweight; Weight Loss; Preventative Health; Body Weight; Cardiovascular Disease Risk Factor
- Interventions
- Noom Weight; Free Tier; Education-only control; Semaglutide; Tirzepatide; Microdose semaglutide; Microdose tirzepatide
- Ages
- adults
- Registry
- NCT07588984
Full record on ClinicalTrials.gov
From the registry
This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement. FLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose). THRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control. Participants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.
Primary outcomes
- Change in Body Weight
- Change in fasting glucose
- Change in HbA1c
- Change in LDL cholesterol
History
Primary completion expected
Last registry update
Started
Registered
In the news
ResearchMedical Xpress (opens Medical Xpress in a new tab)
Semaglutide reduces eating disorder symptoms, improves body image in 120-adult obesity trial
Penn researchers tested a 2.4-mg dose against placebo over 60 weeks, providing lifestyle support in each arm; average weight losses were 15% and 3%, respectively.
ResearchNature Metabolism (opens Nature Metabolism in a new tab)
Rare damaging GLP1R variants blunt semaglutide weight loss but not tirzepatide’s
Researchers compared 33 GLP1R variant carriers with matched noncarriers using sequencing and health records from 13,725 treated adults in the Helix Research Network.
TrialsThe Lancet (opens The Lancet in a new tab)
Regeneron's trevogrumab preserves lean mass during semaglutide weight loss in phase 2 obesity trial
The randomized, placebo-controlled COURAGE trial found trevogrumab generally well tolerated; adding garetosmab increased weight loss and improved body composition but had unfavorable safety and tolerability.
ResearchMedical Xpress (opens Medical Xpress in a new tab)
Resistance training cuts lean mass loss 25% during tirzepatide obesity treatment
In a 40-week randomized trial of 120 adults aged 50–70, three weekly sessions increased strength 10%, versus a 10% decline with tirzepatide alone, researchers report.
Also in Nature Medicine (opens Nature Medicine in a new tab)



